$16.92
+0.65%OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Wall Street analysts project that KIDS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 17.00 to a high of 25.00.
The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 17.00 to a high of 25.00.
Strong upside potential. Consensus indicates attractive return opportunity with favorable risk-reward profile.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
During the last 12 months, insiders have purchased $99K and sold $1.00M worth of KIDS shares, resulting in $905K of net selling activity.
0
0.00
58.2K
1.00M
-1.0M
-$1.00M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
5.1K
98.53K
0
0.00
+99K
+$99K
Hite Fred
Director, Officer: Coo And Cfo
$99K
Bailey David R
Director, Officer: President And Ceo
$337K
Hite Fred
Director, Officer: Coo And Cfo
$224K
Gerritzen Daniel J
Officer: General Counsel And Secretary
$149K
Hauser Joseph W
Officer: Pres. Trauma & Def. Correction
$148K
Odle Gregory A
Officer: President Of Scoliosis
$145K
Strong bearish signal with $905K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
Continue your KIDS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.